Lymphoma and Chronic Lymphocytic Leukemia Update

Issue 2, 2017 (Video Program)

CME Information

TARGET AUDIENCE

This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY

The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains in the management of this group of diseases. Determining which treatment approach is most appropriate requires careful consideration of patient characteristics, physician expertise and available health-system resources. To bridge the gap between research and patient care, this program features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.

LEARNING OBJECTIVES

- Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with Hodgkin lymphoma and other CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.
- Compare and contrast the mechanisms of action, efficacy and safety of approved immunotherapeutic approaches (eg, checkpoint inhibitors, chimeric antigen receptor-directed T-cell therapy) for the treatment of Hodgkin and non-Hodgkin lymphoma to determine the current and/or potential utility of each in clinical practice.
- Consider current and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and relapsed/refractory follicular, mantle cell and diffuse large B-cell lymphomas.
- Formulate an evidence-based treatment approach that incorporates small-molecule inhibitors and third-generation monoclonal antibodies for the treatment of chronic lymphocytic leukemia, and develop a plan to monitor and manage their unique toxicities.
- Assess the benefits of ongoing clinical trials for patients with hematologic cancers, and inform appropriately selected patients about these options for treatment.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide *aggregate* and *deidentified* data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at **ResearchToPractice.com/Privacy-Policy** for more information.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at **ResearchToPractice.com/LymphomaCLLUpdate217/Video/CME**. The corresponding audio program is available as an alternative at **ResearchToPractice.com/LymphomaCLLUpdate217**.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Jeremy Abramson, MD
Director of the Lymphoma Program
Jon and Jo Ann Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc.

Ajay K Gopal, MD
Professor, Medical Oncology Division
University of Washington School of Medicine
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Director of Clinical Research
Hematology Malignancies/Hematology
Seattle Cancer Care Alliance
Seattle, Washington

Advisory Committee: Gilead Sciences Inc, Janssen Biotech Inc, Merck; **Consulting Agreements:** Aptevo Therapeutics, BRIM Biotechnology Inc, Gilead Sciences Inc, Janssen Biotech Inc, Merck, Sanofi Genzyme, Seattle Genetics; **Contracted Research:** Bristol-Myers Squibb Company, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seattle Genetics, Spectrum Pharmaceuticals Inc, Takeda Oncology, Teva Oncology.

EDITOR — **Dr Love** is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc and Seattle Genetics.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: December 2017

Expiration date: December 2018

Select Publications

A phase 3 open label randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma (RELEVANCE). NCT01650701

Andorsky DJ et al. **Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).** *Proc ASCO* 2017;**Abstract 7502**.

Andorsky DJ et al. **MAGNIFY: Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by lenalidomide vs rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone, or mantle cell lymphoma.** *Proc ASH* 2016;**Abstract 1798**.

Burger JA et al; RESONATE-2 Investigators. **Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.** *N Engl J Med* 2015;373(25):2425-37.

Byrd JC et al. **Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia.** *N Engl J Med* 2016;374(4):323-32.

Chen R et al. **Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.** *Blood* 2016;128(12):1562-6.

Furman RR et al. **Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.** *N Engl J Med* 2014;370(11):997-1007.

Goede V et al. **Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.** *N Engl J Med* 2014;370(12):1101-10.

Gopal AK et al. **Continued excellent outcomes in previously untreated follicular lymphoma patients after treatment with CHOP plus rituximab or CHOP plus (131) iodine-tositumomab — Long term follow-up of phase III randomized study SWOG S0016.** *Proc ASH* 2016;**Abstract 616**.

Gopal AK et al. **Sequential RCHOP, radioimmunotherapy and rituximab maintenance improves early outcomes in advanced stage follicular lymphoma: 5 year outcomes from SWOG 0801.** *Proc ASH* 2016;**Abstract 614**.

Lampson BL et al. **Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.** *Blood* 2016;128(2):195-203.

Le Gouill S et al. **Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: Final results of the randomized phase 3 LyMa trial of the Lysa/Goelams Group.** *Proc ASH* 2016;**Abstract 145**.

Marcus R et al. **Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: Primary results of the randomized phase 3 GALLIUM study.** *Proc ASH* 2016;**Abstract 6**.

Moskowitz CH et al. **Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial.** *Lancet* 2015;385(9980):1853-62.

O'Brien S et al. **Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): A phase 2, open-label, multicentre study.** *Lancet Oncol* 2016;17(10):1409-18.

Salles G et al. **Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study.** *Haematologica* 2017;102(4):e156-9.

Sehn LH et al. **Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial.** *Lancet Oncol* 2016;17(8):1081-93.

Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse. *Clin Adv Hematol Oncol* 2016;14(2 Suppl 1):17-8.

Weirda WG et al. **Management of transaminase elevations in patients receiving idelalisib.** *Proc ASCO* 2016;**Abstract 7532**.

Younes A et al. **The landscape of new drugs in lymphoma.** *Nat Rev Clin Oncol* 2017;14(6):335-46.

Zelenetz AD et al. **Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial.** *Lancet Oncol* 2017;18(3):297-311.